Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) reported an attributable net profit of 1.72 billion yuan for the first half, up 1.15% from 1.70 billion yuan a year earlier.
Earnings per share stood at 0.65 yuan, inching up from 0.64 yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.
Revenue increased 4.75% year over year to 20.4 billion yuan from 19.4 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.